Wide Ranks

APLT

Applied Therapeutics, Inc.

8.57

Top Statistics
Market Cap 997 M Forward PE -18.30 Revenue Growth 0.00 %
Current Ratio 1.06 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -9.76 Enterprise / Revenue -4246.60 Price To Sales Trailing12 Months -4703.64
Profitability
Profit Margins 0.00 % Operating Margins -24379.51 %
Balance Sheet
Total Cash 98 M Total Cash Per Share 0.8500 Total Debt 1 M
Total Debt To Equity 33.45 Current Ratio 1.06 Book Value Per Share 0.0510
All Measures
Short Ratio 770.00 % Message Board Id finmb_559189115 Shares Short Prior Month 14 M
City New York Uuid 8f291f10-8e11-3c36-b060-d2cb9f8d8972 Previous Close 10.21
First Trade Date Epoch Utc 1 B Book Value 0.0510 Beta 2.02
Total Debt 1 M Volume 5 M Price To Book 168.04
Fifty Two Week Low 1.85 Total Cash Per Share 0.8500 Total Revenue -212000
Shares Short Previous Month Date 1 B Target Median Price 13.50 Audit Risk 9
Max Age 86400 Recommendation Mean 1.17 Sand P52 Week Change 0.3133
Operating Margins -24379.51 % Target Mean Price 13.50 Net Income To Common -187310000
Short Percent Of Float 0.1301 Implied Shares Outstanding 116 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 3 M Average Volume10days 3 M
Total Cash 98 M Next Fiscal Year End 1 B Revenue Per Share -0.0020
Held Percent Insiders 0.0524 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Share Holder Rights Risk 7 Regular Market Previous Close 10.21
Target Low Price 12.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 8.81
Open 10.25 Free Cashflow -3580125 State NY
Dividend Yield 0.00 % Return On Assets -0.7601 Time Zone Short Name EST
Board Risk 8 Trailing Eps -1.42 Day Low 8.39
Address1 545 Fifth Avenue Shares Outstanding 116 M Compensation Risk 10
Price Hint 2 Target High Price 15.00 Website https://www.appliedtherapeutics.com
52 Week Change 3.06 Average Volume 2 M Forward Eps -0.4600
Recommendation Key strong_buy Compensation As Of Epoch Date 1 B Quick Ratio 100.20 %
Is_sp_500 False Regular Market Day High 10.40 Profit Margins 0.00 %
Debt To Equity 33.45 Fifty Two Week High 10.62 Day High 10.40
Shares Short 13 M Regular Market Open 10.25 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue -4246.60 Revenue Growth 0.00 %
Shares Percent Shares Out 0.1166 Operating Cashflow -81841000 Currency USD
Time Zone Full Name America/New_York Market Cap 997 M Is_nasdaq_100 False
Zip 10017 Quote Type EQUITY Industry Biotechnology
Long Name Applied Therapeutics, Inc. Overall Risk 10 Regular Market Day Low 8.39
Held Percent Institutions 1.02 Current Price 8.57 Address2 Suite 1400
Enterprise To Ebitda -9.76 Financial Currency USD Current Ratio 1.06
Industry Disp Biotechnology Number Of Analyst Opinions 6 Country United States
Float Shares 84 M Two Hundred Day Average 6.20 Governance Epoch Date 1 B
Enterprise Value 900 M Price To Sales Trailing12 Months -4703.64 Forward PE -18.30
Regular Market Volume 5 M Ebitda -92284000 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States.

The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.

It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy.

The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007.

Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.